Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Orally active antiplatelet agents in development at Lafon

Feb. 24, 2000

Approvable letter issued by FDA for Texas Biotechnology's Novastan

Feb. 23, 2000

Immune Response synthesizes new factor VIII gene

Feb. 23, 2000

Lafon presents piperazinone-based antithrombotic agents

Feb. 22, 2000

AstraZeneca portfolio includes new series of P2T antagonists

Feb. 18, 2000

Stroke news: DuPont gpIIb/IIIa antagonist shows promise in ischemic stroke

Feb. 16, 2000

Anti-gpIIb/IIIa MAb fragment proves effective and safe in rat model of embolic stroke

Feb. 16, 2000

FDA extends decision date for Novastan NDA to Feburary 18

Feb. 15, 2000

UroGen cleared to begin phase I human clinical trial of gene therapy for hemophilia A

Feb. 14, 2000

Sibrafiban no better than aspirin in final analysis of SYMPHONY study

Feb. 11, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...